Combo treatment may boost survival with advanced prostate cancer

August 6, 2015 by Steven Reinberg, Healthday Reporter
Combo treatment may boost survival with advanced prostate cancer
Adding chemotherapy to hormone therapy will change practice, expert says.

(HealthDay)—Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds.

Over nearly 29 months of follow-up, with advanced who received the lived almost 14 months longer than men who received only hormone therapy (58 months versus 44 months), researchers said.

"Men who have hormone-sensitive should speak with their doctors about having this combination treatment to significantly prolong their survival," said lead researcher Dr. Christopher Sweeney, an associate professor of medicine at Harvard Medical School.

For 50 years, hormone therapy has been the standard care for these patients, he said. Adding chemotherapy to hormone therapy is worth doing because even though it's not a cure, it does improve survival and quality of life, Sweeney said.

The study was funded by the U.S. National Cancer Institute, and the report was published Aug. 5 online in the New England Journal of Medicine.

For the study, Sweeney and colleagues randomly assigned 790 men with prostate cancer, average age 63, to chemotherapy plus hormone therapy or hormone therapy alone.

In addition to the survival benefit, men who received the combination of chemotherapy and hormone therapy saw their cancer remain dormant for more than 20 months before it began to progress, compared with close to 12 months among those who only received , researchers found.

Sweeney said that side effects of the chemotherapy were mild, in general. Fatigue, low white blood cell count and infection were the most common side effects, the study said. One man died from an unknown cause, though researchers said the death may have been due to the chemotherapy. The man probably should not have been in the trial in the first place, Sweeney said.

One of the criteria for the treatment is that patients should be able to handle the chemotherapy, Sweeney said. If they have other conditions such as liver or kidney disease, they should not be getting chemotherapy, he said.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said, "This is an important study that will change practice."

In the study, the greatest benefit was seen in men who had four or more tumors outside the prostate, but D'Amico, who wasn't involved with the research, believes will also help men with fewer tumors. "It will probably work across the board," he said.

Other studies, D'Amico said, have confirmed these findings. "This drives home the point that we should change practice," he said.

"It's not curing prostate cancer," he said. "But it's certainly increasing the time people have."

Explore further: Treatment extends life for men with prostate cancer

More information: Paper: www.nejm.org/doi/full/10.1056/NEJMoa1503747

For more information on prostate cancer, visit the American Cancer Society.

Related Stories

Treatment extends life for men with prostate cancer

June 1, 2014
A new treatment has been shown to extend the lifespans of men with advanced prostate cancer by as much as one year, researchers said Sunday.

Drug combination extends survival by more than a year in metastatic prostate cancer

June 2, 2014
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to ...

Adding chemotherapy to standard prostate cancer treatment may extend life expectancy

May 14, 2015
New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared ...

Intraperitoneal chemotherapy ups ovarian cancer outcomes

August 5, 2015
(HealthDay)—Intraperitoneal chemotherapy significantly improves survival among women with advanced ovarian cancer; however, fewer than half of eligible U.S. patients are receiving it, according to research published online ...

Study identifies possible new combination chemotherapy for patients with advanced prostate cancer

May 31, 2015
For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel ...

Radiation plus hormone therapy prolongs survival for older men with prostate cancer

January 5, 2015
Adding radiation treatment to hormone therapy saves more lives among older men with locally advanced prostate therapy than hormone therapy alone, according to a new study in the Journal of Clinical Oncology this week from ...

Recommended for you

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.